Skip to main content
VITEK MS PRIME service

A partner you can trust for COVID-19 Testing & Management

COVID-19 / SARS-CoV-2

Because every COVID-19 patient comes with a unique profile and experiences the disease differently, patient management means asking the right questions, finding the right answers and providing appropriate care the entire length of the patient pathway.

What if you had COVID-19 diagnostic support and management from primary diagnosis to discharge and follow up?

What is COVID-19 / SARS-CoV-2?

On March 11, 2020, The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic, known worldwide as COVID-19.1 Caused from the SARS-CoV-2 virus, COVID-19 has continued to be an ongoing, unprecedented global health challenge and a significant cause of morbidity and mortality, exacting a huge economic cost around the world.  

Patients with suspected COVID-19 present with a broad array of signs and symptoms – many of which can also be caused by other diseases. Additionally, patients with severe COVID-19 infections frequently experience secondary opportunistic infections.  Fast and accurate testing is essential for diagnosing and reducing the spread of COVID-19.  bioMérieux was proud to be a part of the global response with the development of 3 of the first commercially available diagnostic tests for SARS-CoV-2, along with additional critical tests for COVID-19 patient management.

COVID-19: From Pandemic to Common Respiratory Infection

Since the SARS-CoV-2 virus first emerged in 2019, the circulation of the virus has changed and shifted from a pandemic to seasonal circulation. Paired with the re-emergence of main winter respiratory viruses (Influenza A, Influenza B, and RSV), it is critical that clinicians discriminate the virus to best provide appropriate patient care. Several respiratory pathogens have similiar symptoms, and so the availability and accuracy of the right type of tests to deliver actionable results is critical to insure optimized patient treatment and management.

Our unique and full portfolio of diagnostic tools for COVID-19 offer you:

  • Improved patient outcomes
  • Decreased morbidity
  • Decreased contamination risk
  • Improved antibiotic stewardship (decrease in the use and duration of antibiotics)
  • Reduction in unnecessary or ancillary testing
  • Reduction in hospital admissions
  • Reduction in length of stay
  • Reduction in hospital-acquired infections

COVID-19 / SARS-CoV-2 - Our Diagnostic Offer

A Comprehensive Diagnostic Approach

COVID-19 Patient Management requires healthcare professionals to be alert to the patient’s needs throughout the entire patient pathway.  bioMérieux is proud to offer a comprehensive range of diagnostic tools to support COVID-19 patient care. From primary diagnosis and testing of SARS-CoV-2 to patient discharge, bioMérieux supports you at every step.

Diagnostic Tools

Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country.

Because patients with suspected COVID-19 present with an array of symptoms that can be caused by other infections and diseases, it is critical that the initial diagnoses are completed with tests that have the necessary high quality, validation, and regulatory market approvals. This assures patient, physician, and lab professional confidence. bioMérieux offers tests that not only diagnose SARS-CoV-2, but other respiratory infections as well that may have similar symptoms to COVID-19.

  • VIDAS® SARS-COV-2 

    Two immunoassay tests to detect IgM & IgG antibodies

    VIDAS® SARS-COV-2 IgM and VIDAS® SARS-COV-2 IgG II automated qualitative assays rapidly detect antibodies to help identify individuals with previous exposure to SARS-CoV-2.

  • BIOFIRE® FILMARRAY® TORCH

    Easier testing. Faster results.

    Syndromic infectious disease testing with BIOFIRE® FILMARRAY® TORCH is the fastest way to better results.

  • BIOFIRE® Respiratory 2.1 and 2.1plus Panels

    1 Test. Up to 23 Targets. ~45 Minutes.

    The BIOFIRE RP2.1 and RP2.1plus Panels use the syndromic approach to accurately detect and identify the pathogens most associated with respiratory infections. Fast and comprehensive results may enable better-informed diagnosis and treatment of patients.

  • BIOFIRE® SPOTFIRE® System

    This Changes Everything.

    SPOTFIRE® System is the latest advancement in molecular infectious disease diagnostics from bioMérieux. All our expertise and cutting-edge FILMARRAY® technology is at the heart of the system design.

    SPOTFIRE® offers a multiplex PCR solution for Point-of-care testing, offering rapid and actionable results onsite. It can run syndromic test on 1,2,3 or 4 modules and automates molecular results in minutes.

  • BIOFIRE® SPOTFIRE® Respiratory Panels

    Comprehensive Onsite PCR Results in ~15 Minutes.

    Point-of-care respiratory testing solutions with SPOTFIRE Respiratory Panels offering rapid syndromic PCR tests for a range of common pathogens.

  • Previous
  • 1
  • Next

Diagnosing the correct respiratory causative agent is critical, but understanding the severity of the disease is equally as important. bioMérieux offers tests that indicate infection severity to support informed decision-making and improved patient care.

  • VIDAS® B•R•A•H•M•S PCT™

    Important Biomarker for Improved Patient Management

    Detects procalcitonin, a biomarker that aids in the risk assessment for progression to severe sepsis and septic shock. PCT also aids in decision making on antibiotic therapy for patients with lower respiratory tract infections (LRTI).

  • VIDAS® D-DIMER EXCLUSION™ II

    Safe Exclusion of Venous Thromboembolism

    VIDAS® D-Dimer Exclusion™ II is a highly-sensitive automated D-Dimer assay. Used in conjunction with assessment of clinical pretest probability, it allows safe exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE) in both low and intermediate suspected outpatient risk groups in just 20 minutes.

  • VIDAS® NT-proBNP 2

    Exclusion or Confirmation of Acute Heart Failure

    VIDAS® NT-proBNP2 is a useful tool for rapid and clinical assessment and diagnosis of patients with symptoms of suspected heart failure.

    High sensitivity and specificity allows initiation of timely, appropriate treatment.

    Cost-effective tool adapted to emergency situations.

  • VIDAS® NEPHROCHECK®

    Reveal Kidney Stress Early. Drive Better Outcomes.

    VIDAS® NEPHROCHECK® measures urinary TIMP-2 & IGFBP-7, specific urinary biomarkers for early risk assessment of moderate to severe Acute Kidney Injury (AKI). The VIDAS® NEPHROCHECK® assay is intended to be used in conjunction with clinical evaluation as an aid in the risk assessment for moderate or severe acute kidney injury (AKI) in acutely ill patients.

  • VIDAS® KUBE™

    Stackable benchtop automated immunoassay solution

    VIDAS® KUBE™ is designed to preserve everything labs appreciate about the VIDAS® Solution combined with advanced technology. VIDAS® KUBE™ is a truly flexible, cost-effective automated immunoassay solution providing fast results in complete confidence.

  • VIDAS® 3

    Trusted. Robust. Innovative.

    With its advanced immunoassay technology and optimized testing protocols, the fully automated VIDAS® 3 benchtop immunoanalyzer empowers your lab with confidence, offering the precise results you need, when you need them. 

  • Previous
  • 1
  • Next

Often, patients with COVID-19 will develop secondary infections that need to be both addressed and managed. bioMérieux offers a variety of tests to determine if patients are suffering from additional blood, cardiovascular, and/or respiratory infection to optimize patient management.

  • BIOFIRE® FILMARRAY® TORCH

    Easier testing. Faster results.

    Syndromic infectious disease testing with BIOFIRE® FILMARRAY® TORCH is the fastest way to better results.

  • BIOFIRE® Respiratory 2.1 and 2.1plus Panels

    1 Test. Up to 23 Targets. ~45 Minutes.

    The BIOFIRE RP2.1 and RP2.1plus Panels use the syndromic approach to accurately detect and identify the pathogens most associated with respiratory infections. Fast and comprehensive results may enable better-informed diagnosis and treatment of patients.

  • BIOFIRE® FILMARRAY® Pneumonia & Pneumonia plus Panels

    1 Test. Up to 34 Targets. ~1 Hour.

    Syndromic tests targeting a comprehensive menu of bacteria and viruses that cause pneumonia and other lower respiratory tract infections, as well as 7 genetic markers of antibiotic resistance.

  • BIOFIRE® Blood Culture Identification 2 Panel

    1 Test. 43 Targets. ~1 Hour.

    The BIOFIRE BCID2 Panel tests for 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeast, and 10 antimicrobial resistance genes – all with one test and with results available in about an hour from positive blood culture.

  • EMAG® 

    Nucleic Acid Extraction System

    EMAG® offers efficient and flexible extraction to manage both routine and challenging customer needs, supported by a committed and skilled team at bioMérieux.

  • BACT/ALERT® 3D

    Accurate Blood Culture Results

    BACT/ALERT® 3D brings flexible and modular automated detection systems for any size laboratory that needs to meet blood culture guidelines efficiently, economically, and effectively.

  • PREVI® COLOR GRAM

    A Market-Leading Automated Gram Stainer Offering Confidence in Results

    Gram staining is a key step in your microbiology workflow, and PREVI® COLOR GRAM is the system to streamline it and provide timely staining results for impactful decisions.

  • VITEK® MS PRIME

    New-Generation Mass Spectrometry Microbial Identification System

    VITEK® MS PRIME combines microbiology expertise with innovation taking mass spectrometry to the next level by maximizing the impact of daily laboratory workflow for better patient care. 

  • VITEK® 2

    Fully integrated Identification and Antimicrobial Susceptibility Testing

    VITEK® 2, the leading automated system for routine antimicrobial susceptibility testing, provides efficient workflow, faster AST results. Its fully-integrated ID & AST approach ensures superior performance to rapidly and confidently guide therapy.

  • CHROMID®

    Chromogenic Media for Organism Isolation and Identification

    Innovative and extensive range of chromogenic media for the simultaneous culture and identification of microorganisms in clinical specimens.
  • Previous
  • 1
  • Next

If a bacterial co-infection or secondary bacterial infection is realized with a COVID-19 patient, then it is necessary for antimicrobial treatment selection and monitoring to take place. As a leader in ID/AST, bioMérieux offers trusted and innovative products that give hospitals and laboratories the right analysis for relevant treatment options.

  • VIDAS® B•R•A•H•M•S PCT™

    Important Biomarker for Improved Patient Management

    Detects procalcitonin, a biomarker that aids in the risk assessment for progression to severe sepsis and septic shock. PCT also aids in decision making on antibiotic therapy for patients with lower respiratory tract infections (LRTI).

  • VITEK® 2

    Fully integrated Identification and Antimicrobial Susceptibility Testing

    VITEK® 2, the leading automated system for routine antimicrobial susceptibility testing, provides efficient workflow, faster AST results. Its fully-integrated ID & AST approach ensures superior performance to rapidly and confidently guide therapy.

  • ETEST®

    Antibiotic Susceptibility Testing Reagent Strips to Determine On-Scale MICs

    Clinicians often need more information than what primary AST can provide. Recognized around the world for their proven performance, ETEST® ready to use reagent strips determine on-scale MICs.

  • Previous
  • 1
  • Next

Diagnostic tests play a crucial role in deciding when it is safe for COVID-19 patients to be discharged from healthcare facilities. After discharge, some patients may also require follow-up tests to assess potential relapses or complications, in addition to assessing immune response.

  • VIDAS® SARS-COV-2 

    Two immunoassay tests to detect IgM & IgG antibodies

    VIDAS® SARS-COV-2 IgM and VIDAS® SARS-COV-2 IgG II automated qualitative assays rapidly detect antibodies to help identify individuals with previous exposure to SARS-CoV-2.

  • SARS-COV-2 FLUA/FLUB/RSV R-GENE®

    Real-time PCR detection kit

    Detect & differentiate SARS-CoV-2, Influenza A, Influenza B and RSV in 1 PCR test.

  • EMAG® 

    Nucleic Acid Extraction System

    EMAG® offers efficient and flexible extraction to manage both routine and challenging customer needs, supported by a committed and skilled team at bioMérieux.

  • Previous
  • 1
  • Next

  • BIOMÉRIEUX EPISEQ®

    Next Generation Sequencing (NGS) Data Analysis Platform

    Provides easy-to-use applications for clinical microbiologists: clinical pathogen outbreak management, microbiome profiling, and SARS-CoV-2 genomics variants identification.

  • BIOFIRE® Syndromic Trends

    Turn BIOFIRE® System Results into Smart Pathogen Trending

    Creating a global surveillance network that displays BIOFIRE® Panel test results from participating laboratories and hospitals around the world, BIOFIRE TREND allows users to explore epidemiology insights and better understand site-specific and regional pathogen trends and seasonality. 

  • Previous
  • 1
  • Next

  • VILINK®

    Optimize Instrument UPTIME to Improve Laboratory Productivity

    A secure solution offering remote access, proactive maintenance, and remote updates. VILINK® diagnoses, solves software and instrument issues, and supports your systems to enable laboratory productivity and efficiency improvements. 

  • BIOMÉRIEUX EPISEQ®

    Next Generation Sequencing (NGS) Data Analysis Platform

    Provides easy-to-use applications for clinical microbiologists: clinical pathogen outbreak management, microbiome profiling, and SARS-CoV-2 genomics variants identification.

  • BIOMÉRIEUX LAB CONSULTANCY

    Microbiology Expertise and Consultancy to Optimize Lab Performance

    Transforming laboratories together to control costs, maximize quality, shorten time to result, and empower staff.

  • Previous
  • 1
  • Next

Contact Us About Our COVID-19 / SARS-CoV-2 Solutions

Contact Us

       

    References

    1WHO Director-General’s opening remarks at the media briefing on COVID19 -March 2020